Effect of a Low Advanced Glycation End Products (AGE) Diet in the Metabolic Syndrome
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
The investigators have previously demonstrated that Advanced Glycation End products (AGEs) are associated with several chronic diseases in humans and that blood AGE levels can be significantly reduced by simply changing the way food is cooked.
This is an interventional-randomized study in which we are trying to determine whether a diet low in AGE followed for 1 year can effectively reduce circulating AGE levels as well as markers of the metabolic syndrome in a group of patients with these abnormal markers.
Full description
The metabolic syndrome (MetSyn), a well-defined cluster of pathogenic conditions, includes glucose intolerance, insulin resistance (pre-diabetes), hypertension, abdominal obesity, and dyslipidemia. The MetSyn has a strong inflammatory component and raises the risk for cardiovascular disease (CVD) by five-fold and of diabetes by two fold in aging. Although, excessive caloric intake, i.e. "over nutrition" is known to be involved in developing the MetSyn, the actual causative agents of MetSyn in human nutrition have not been determined.
The investigators have previously shown that Advanced Glycation End products (AGEs) can induce oxidant stress and inflammatory responses and modulate insulin signaling in animal models and more recently in humans. These studies separated the effects of "over-nutrition" from the pro-inflammatory effects of AGEs, a factor not previously considered. These data support our hypothesis that AGE-restriction could be an important intervention in the MetSyn in aging.
The investigators would like to demonstrate that this safe, practical and economical intervention can arrest the progression of three major "epidemics" of aging: diabetes, obesity, and vascular disease associated with the metabolic syndrome. This simple intervention could have significant health and economic implications.
Our hypothesis is that dietary AGE restriction can reverse several cardinal manifestation of the MetSyn, specifically insulin resistance, abdominal obesity and cardiovascular disease.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
-
Non-smoking adult subjects with at least three of the following five characteristics of the metabolic syndrome (MetSyn):
- Waist circumference:
Men: > 102 cm Women: > 88 cm
- Blood pressure: > 130/85 mm Hg (or use of anti-Blood Pressure medication)
- HDL-cholesterol:
Men: < 40 mg/dL Women: < 50 mg/dL
-
Triglycerides: > 150 mg/dL (or use of medications for high triglycerides such as fibrates or nicotinic acid)
-
Fasting blood sugar > 100 mg/dl (or use of metformin), but a Glycated hemoglobin (HbA1c) <6.5%
- Any gender and race 50 years old or above
- Dietary AGE intake > 12 AGE Eq/day
(Before randomization all participants will be screened with a 3-day food record and 7-day food frequency questionnaire (AGE Quick Score) to determine their average spontaneous daily intake of AGEs. Only those subjects whose daily intake is > 12 AGE Eq/day will participate in the study.)
Exclusion criteria
- Diagnosis of diabetes (HbA1C > 6.5 %)
- Glomerular Filtration Rate (GFR) less than 60 ml/min
- Any major cardiovascular event within the preceding 3 months
- Inability to understand or unwillingness to follow study diets
- Any unstable medical condition requiring medication adjustment or treatment within the preceding 3 months
- Any severe illness with an expected participant survival less than 1 year
- Diagnosis of HIV
- Currently receiving treatment for any inflammatory condition
- Currently receiving cancer treatment, such as radiation, chemotherapy, hormone therapy, or stem cell transplant
- Currently participating in any other research study requiring a special diet, medications, supplements or other lifestyle change
Trial design
Primary purpose
Allocation
Interventional model
Masking
383 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal